MK-677 (Ibutamoren) + MOTS-c Stack: Safety and Monitoring Guide

What MK-677 (Ibutamoren) Does and Why It Creates Metabolic Risk

MK-677 is a non-peptide ghrelin-receptor agonist taken orally. It stimulates pulsatile growth hormone release from the pituitary and, downstream, raises IGF-1 concentrations. Unlike injected GH, it does not bypass natural feedback loops entirely, but it still produces sustained elevation of GH and IGF-1 that carries consequences for glucose metabolism.

Mechanism of GH Elevation

MK-677 binds the growth hormone secretagogue receptor 1a (GHSR-1a) with high affinity. In the Phase II trial by Nass et al. (N=65, 2-year duration), MK-677 at 25 mg/day raised IGF-1 by approximately 60% above baseline in older adults [1]. GH elevation at this magnitude directly reduces insulin-stimulated glucose uptake in peripheral tissues, a well-characterized counter-regulatory mechanism.

The Glucose Problem

Fasting glucose and fasting insulin both rise on MK-677. In the Nass 2-year trial, fasting blood glucose increased by a mean of 0.3 mmol/L (roughly 5.4 mg/dL) versus placebo [1]. That increment is modest in isolation, but in pre-diabetic individuals or those with metabolic syndrome, it may push fasting glucose above the diagnostic threshold of 5.6 mmol/L (100 mg/dL) set by the American Diabetes Association [2].

IGF-1 Elevation: Benefit and Risk in the Same Number

IGF-1 drives muscle protein synthesis and supports bone mineral density, which are the primary reasons people stack MK-677. The IGF-1 reference range for adults aged 30 to 60 is approximately 88 to 246 ng/mL depending on the assay [3]. Supplementing MK-677 at 25 mg/day can push IGF-1 to the upper quartile or above. Values persistently above 300 ng/mL have been associated with increased colorectal cancer risk in epidemiological cohorts, though causality is not established [4].

What MOTS-c Does and What the Evidence Actually Shows

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded in mitochondrial DNA. It was identified by Lee et al. In 2015 and has since attracted substantial preclinical interest for its role in metabolic regulation [5].

Mechanism: AMPK Activation and Insulin Sensitization

MOTS-c activates AMP-activated protein kinase (AMPK) and the folate cycle-AICAR pathway in skeletal muscle. In the original 2015 mouse study, MOTS-c administration reversed high-fat diet-induced insulin resistance and obesity in C57BL/6 mice within 4 weeks [5]. AMPK activation in skeletal muscle mimics the metabolic effects of exercise, increasing glucose transporter 4 (GLUT4) translocation and reducing hepatic glucose output.

Human Data: Early and Limited

The human evidence base for MOTS-c is thin. A 2019 cross-sectional study found that circulating MOTS-c levels decline with age in both men and women and are inversely correlated with body mass index and fasting insulin [6]. A 2021 study in older adults found that plasma MOTS-c was lower in individuals with type 2 diabetes than in matched controls [7]. These associations are hypothesis-generating, not proof of therapeutic effect.

No Phase II or Phase III clinical trial of exogenous MOTS-c has been completed and published as of early 2025. The compound is not FDA-approved for any indication.

Exercise Interaction

MOTS-c levels rise acutely with intense aerobic exercise in humans [8]. This observation suggests that exogenous MOTS-c might amplify the metabolic benefit of exercise-paired training, which is relevant for the physique or performance use cases where MK-677 is most commonly sought.

Why People Stack MK-677 with MOTS-c: The Theoretical Rationale

The combination is conceptually appealing because the two compounds appear to act on opposite sides of the same metabolic problem. MK-677 raises IGF-1 and GH, promoting anabolism, while also worsening insulin sensitivity. MOTS-c improves insulin sensitivity through AMPK and GLUT4 mechanisms. The hypothesis is that MOTS-c corrects the glucose liability that MK-677 introduces.

This creates a three-part rationale that clinicians evaluating this stack should examine:

1. Anabolic signal. MK-677 at 25 mg/day raises IGF-1 by roughly 60% [1], driving muscle protein synthesis at the receptor level.
2. Glucose offset hypothesis. MOTS-c activates AMPK in skeletal muscle, the primary tissue responsible for postprandial glucose clearance. In the Lee 2015 mouse model, AMPK activation restored normal insulin sensitivity in diet-induced obese animals [5].
3. Mitochondrial support. MOTS-c may preserve mitochondrial membrane potential under anabolic stress, though this mechanism has not been studied in the context of GH secretagogue co-administration.

None of these three theoretical rationale points have been tested in a human combination study. The evidence for each element in isolation is asymmetric: MK-677 has Phase II human data [1], while MOTS-c relies primarily on mouse studies and human correlational data.

Safety Concerns Specific to the Stack

Glucose Monitoring Is Non-Negotiable

The single most clinically significant risk is additive glycemic burden. MK-677 alone raises fasting glucose. If MOTS-c fails to offset this effect in a given individual (which is entirely possible given the absence of direct evidence), the user will accumulate insulin resistance over weeks to months without obvious symptoms.

The American Association of Clinical Endocrinology recommends HbA1c screening at baseline and every 3 months when initiating agents known to affect glucose homeostasis [9]. That standard applies here. A fasting glucose above 5.6 mmol/L (100 mg/dL) or an HbA1c at or above 5.7% at any monitoring point should prompt dose reduction or stack discontinuation.

IGF-1 Overshoot

Running MK-677 at 25 mg nightly without periodic IGF-1 measurement creates the risk of sustained supraphysiologic IGF-1. The Endocrine Society's clinical practice guideline on growth hormone deficiency states that IGF-1 should be maintained within the age- and sex-adjusted normal range during any GH-axis stimulating therapy [10]. Supraphysiologic IGF-1 above 300 ng/mL for extended periods may increase the proliferative signaling implicated in colorectal and prostate cancer risk [4].

Edema and Carpal Tunnel

MK-677 causes dose-dependent fluid retention through GH-mediated sodium reabsorption. In Phase II trials, peripheral edema occurred in approximately 7 to 8% of participants at 25 mg/day [1]. Carpal tunnel syndrome, also GH-related, was reported in 2 to 4% of participants. These effects are typically reversible with dose reduction.

Injection-Site and Peptide-Purity Risks for MOTS-c

MOTS-c is not available through FDA-approved channels. Research-grade MOTS-c sourced from peptide suppliers carries risks related to:

• Purity. Third-party mass spectrometry testing of peptide vendor products has found wide variability in peptide purity, sometimes below 90% [11].
• Sterility. Subcutaneous injection of non-sterile preparations introduces infection risk.
• Dosing uncertainty. The effective human dose of MOTS-c is unknown. The mouse doses used in Lee et al. Were 15 mg/kg intraperitoneally [5], which does not translate directly to human subcutaneous dosing.

Lipid Profile Changes

GH elevation through MK-677 modestly reduces LDL cholesterol in some studies but may raise fasting triglycerides. A lipid panel at baseline and at 12 weeks is reasonable.

Monitoring Protocol: Labs and Frequency

The monitoring schedule below is a synthesis of existing GH-secretagogue guidance and general peptide safety principles. No guideline specifically addresses the MK-677 plus MOTS-c combination.

Baseline Labs (Before Starting)

| Lab | Rationale | |---|---| | Fasting glucose | MK-677 glucose risk baseline | | Fasting insulin | Detect pre-existing insulin resistance | | HbA1c | 3-month glycemic average | | IGF-1 (age/sex-adjusted) | GH-axis baseline | | Lipid panel (total, LDL, HDL, triglycerides) | MK-677 lipid effects | | Comprehensive metabolic panel | Hepatic and renal function | | CBC | General safety | | PSA (males over 40) | IGF-1 and prostate risk signal |

Week 8 Check-In Labs

Repeat fasting glucose, fasting insulin, and IGF-1. If IGF-1 has risen above the upper limit of the sex- and age-adjusted normal range, reduce MK-677 to 10 mg nightly. If fasting glucose exceeds 100 mg/dL (5.6 mmol/L), reduce MK-677 or pause MOTS-c and recheck in 4 weeks.

Week 16 Full Panel

Repeat the complete baseline panel. This is the decision point for continuation versus discontinuation. HbA1c at week 16 reflects the average glycemic exposure since week 4, providing a cleaner signal than any single fasting glucose reading.

Ongoing Every 12 Weeks

IGF-1, fasting glucose, and HbA1c every 12 weeks for the duration of use. Annual comprehensive panel including PSA in males.

Dosing Protocols Reported in Clinical and Research Settings

No consensus dosing protocol for this stack exists. The following represents the range seen in the literature for each compound individually, adapted to the stack context.

MK-677 Dosing

The Phase II Nass trial used 25 mg/day orally [1]. The lower dose of 10 mg/day produces measurable IGF-1 elevation with a modestly reduced glucose burden. For stack use, starting at 10 mg nightly and titrating to 25 mg nightly over 4 weeks limits the glucose spike while allowing IGF-1 to be measured at each titration step.

MK-677 is taken orally, once nightly, because GH secretion is predominantly nocturnal and evening dosing aligns with the endogenous pulse. Food does not significantly affect bioavailability, but high-carbohydrate meals before dosing can blunt the GH response through somatostatin release.

MOTS-c Dosing

No approved human dose exists. Investigational and practitioner-reported use has ranged from 5 mg to 10 mg subcutaneously, 2 to 3 times per week. Some protocols front-load with daily injection for 2 weeks then shift to a maintenance schedule of 3 times per week. Given the absence of pharmacokinetic data in humans, conservative dosing at 5 mg three times per week is preferable to daily higher-dose use.

Subcutaneous injection sites should be rotated (abdomen, lateral thigh, lateral upper arm) to minimize lipodystrophy at the injection site.

Cycle Length

MK-677 has been studied for up to 2 years in older adults without catastrophic safety signals [1]. However, most performance-oriented users run cycles of 16 to 24 weeks with 8 to 12 weeks off. MOTS-c cycle lengths are arbitrary given the absence of long-term human data; pairing the MOTS-c cycle to the MK-677 cycle is a reasonable default.

Evidence Gaps and What Practitioners Should Tell Patients

The evidence supporting this stack rests on three separate and incomplete bodies of literature:

1. Phase II human data for MK-677 alone, covering GH and IGF-1 elevation and glucose effects [1].
2. Preclinical animal data for MOTS-c, covering insulin sensitization through AMPK [5].
3. Human correlational data for MOTS-c, covering age-related decline and metabolic associations [6, 7].

No study has examined these two compounds together in any species. The "glucose offset" hypothesis is mechanistically coherent but entirely unproven.

The Endocrine Society's position on unproven peptide therapies states: "Physicians should counsel patients that the long-term safety and efficacy of most research peptides have not been established in rigorous clinical trials, and use outside approved indications carries unknown risk" [10].

Practitioners operating within a telehealth model should document this informed-consent conversation explicitly. Patients should understand that MOTS-c is not FDA-approved, that its purity from commercial research suppliers is not guaranteed, and that the combination with MK-677 introduces additive unknowns.

Contraindications and Populations Who Should Not Use This Stack

The following groups carry materially higher risk from MK-677 and should avoid this stack:

• Active or prior malignancy. IGF-1 elevation is potentially mitogenic. The FDA label for recombinant IGF-1 products includes an oncology warning; the same signal applies to agents that raise endogenous IGF-1 [12].
• Type 2 diabetes or pre-diabetes with HbA1c at or above 5.7%. MK-677-induced glucose elevation may push these individuals into overt diabetic range.
• Severe cardiomegaly or history of congestive heart failure. MK-677 in the METS trial (N=292) showed no benefit and a trend toward harm in elderly patients with hip fracture, including increased congestive heart failure events [13].
• Pregnancy and breastfeeding. No safety data exist for either compound in pregnancy.
• Age <18. Open epiphyses create unpredictable bone-growth effects with exogenous GH-axis stimulation.

Practical Checklist Before Starting the Stack

A supervising clinician should verify the following before a patient initiates MK-677 plus MOTS-c:

• Baseline labs completed (see table above).
• No active or prior hormone-sensitive malignancy.
• Fasting glucose <100 mg/dL and HbA1c <5.7% at baseline.
• Patient understands MOTS-c lacks FDA approval and long-term human safety data.
• MOTS-c source includes certificate of analysis from an independent, third-party lab with mass spectrometry confirmation of purity >98%.
• Monitoring schedule confirmed: labs at weeks 8, 16, and every 12 weeks thereafter.
• Physician contact protocol established for symptoms of edema, carpal tunnel, or unexpected fasting glucose rise.